Literature DB >> 31171590

Burosumab Therapy for X-Linked Hypophosphatemia and Therapeutic Implications for CKD.

Farzana Perwad1, Anthony A Portale2.   

Abstract

Entities:  

Keywords:  CKD; FGF23; Familial Hypophosphatemic Rickets; Genetic Linkage; Hypophosphatemia, Familial; Renal Insufficiency, Chronic; Vitamin D; burosumab; phosphorus; rickets

Year:  2019        PMID： 31171590      PMCID： PMC6625611          DOI： 10.2215/CJN.15201218

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  9 in total

1.  FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality.

Authors:  Victoria Shalhoub; Edward M Shatzen; Sabrina C Ward; James Davis; Jennitte Stevens; Vivian Bi; Lisa Renshaw; Nessa Hawkins; Wei Wang; Ching Chen; Mei-Mei Tsai; Russell C Cattley; Thomas J Wronski; Xuechen Xia; Xiaodong Li; Charles Henley; Michael Eschenberg; William G Richards
Journal:  J Clin Invest       Date:  2012-06-25       Impact factor: 14.808

2.  Burosumab Therapy in Children with X-Linked Hypophosphatemia.

Authors:  Thomas O Carpenter; Michael P Whyte; Erik A Imel; Annemieke M Boot; Wolfgang Högler; Agnès Linglart; Raja Padidela; William Van't Hoff; Meng Mao; Chao-Yin Chen; Alison Skrinar; Emil Kakkis; Javier San Martin; Anthony A Portale
Journal:  N Engl J Med       Date:  2018-05-24       Impact factor: 91.245

3.  A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis.

Authors:  Karl L Insogna; Karine Briot; Erik A Imel; Peter Kamenický; Mary D Ruppe; Anthony A Portale; Thomas Weber; Pisit Pitukcheewanont; Hae Il Cheong; Suzanne Jan de Beur; Yasuo Imanishi; Nobuaki Ito; Robin H Lachmann; Hiroyuki Tanaka; Farzana Perwad; Lin Zhang; Chao-Yin Chen; Christina Theodore-Oklota; Matt Mealiffe; Javier San Martin; Thomas O Carpenter
Journal:  J Bone Miner Res       Date:  2018-06-26       Impact factor: 6.741

Review 4.  A clinician's guide to X-linked hypophosphatemia.

Authors:  Thomas O Carpenter; Erik A Imel; Ingrid A Holm; Suzanne M Jan de Beur; Karl L Insogna
Journal:  J Bone Miner Res       Date:  2011-05-02       Impact factor: 6.741

5.  Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease.

Authors:  Hisashi Hasegawa; Nobuo Nagano; Itaru Urakawa; Yuji Yamazaki; Kousuke Iijima; Toshiro Fujita; Takeyoshi Yamashita; Seiji Fukumoto; Takashi Shimada
Journal:  Kidney Int       Date:  2010-09-15       Impact factor: 10.612

Review 6.  A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease.

Authors:  Tamara Isakova; Orlando M Gutiérrez; Myles Wolf
Journal:  Kidney Int       Date:  2009-07-15       Impact factor: 10.612

Review 7.  Bone and mineral disorders in chronic kidney disease: implications for cardiovascular health and ageing in the general population.

Authors:  Adrian Covic; Marc Vervloet; Ziad A Massy; Pablo Ureña Torres; David Goldsmith; Vincent Brandenburg; Sandro Mazzaferro; Pieter Evenepoel; Jordi Bover; Mugurel Apetrii; Mario Cozzolino
Journal:  Lancet Diabetes Endocrinol       Date:  2017-10-16       Impact factor: 32.069

8.  Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia.

Authors:  Yukiko Aono; Yuji Yamazaki; Junichi Yasutake; Takehisa Kawata; Hisashi Hasegawa; Itaru Urakawa; Toshiro Fujita; Michihito Wada; Takeyoshi Yamashita; Seiji Fukumoto; Takashi Shimada
Journal:  J Bone Miner Res       Date:  2009-11       Impact factor: 6.741

9.  FGF23 effects on the heart-levels, time, source, and context matter.

Authors:  Christian Faul
Journal:  Kidney Int       Date:  2018-07       Impact factor: 10.612
  9 in total
  5 in total

1.  Hypophosphatemic rickets accelerate chondrogenesis and cell trans-differentiation from TMJ chondrocytes into bone cells via a sharp increase in β-catenin.

Authors:  Hui Li; Yan Jing; Rong Zhang; Qi Zhang; Jun Wang; Aline Martin; Jian Q Feng
Journal:  Bone       Date:  2019-11-18       Impact factor: 4.398

2.  Identification of core genes and pathways between geriatric multimorbidity and renal insufficiency: potential therapeutic agents discovered using bioinformatics analysis.

Authors:  Lingyun Zhang; Jiasheng Cai; Jing Xiao; Zhibin Ye
Journal:  BMC Med Genomics       Date:  2022-10-08       Impact factor: 3.622

Review 3.  Clinical Potential of Targeting Fibroblast Growth Factor-23 and αKlotho in the Treatment of Uremic Cardiomyopathy.

Authors:  Jonathan P Law; Anna M Price; Luke Pickup; Ashwin Radhakrishnan; Chris Weston; Alan M Jones; Helen M McGettrick; Winnie Chua; Richard P Steeds; Larissa Fabritz; Paulus Kirchhof; Davor Pavlovic; Jonathan N Townend; Charles J Ferro
Journal:  J Am Heart Assoc       Date:  2020-03-26       Impact factor: 5.501

Review 4.  Bone Quality in Chronic Kidney Disease Patients: Current Concepts and Future Directions - Part II.

Authors:  Kamyar Asadipooya; Mohamed Abdalbary; Yahya Ahmad; Elijah Kakani; Marie-Claude Monier-Faugere; Amr El-Husseini
Journal:  Kidney Dis (Basel)       Date:  2021-04-26

5.  An Expert Perspective on Phosphate Dysregulation With a Focus on Chronic Hypophosphatemia.

Authors:  Fahad Aljuraibah; Justine Bacchetta; Maria Luisa Brandi; Pablo Florenzano; Muhammad K Javaid; Outimaija Mäkitie; Adalbert Raimann; Mariano Rodriguez; Heide Siggelkow; Dov Tiosano; Marc Vervloet; Carsten A Wagner
Journal:  J Bone Miner Res       Date:  2021-12-23       Impact factor: 6.390
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.